Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"

CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipe

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Con

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the anal

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) to

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the p

CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on t

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely e

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.

Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therap

Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by

CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved as

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move

CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the pr

CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) w

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the te

Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Per

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overwei

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshad

- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offe

US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy an

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pip

TD Cowen analyst Tyler Van Buren maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and rais

Evercore ISI Group analyst Liisa Bayko maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperf

Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the pr

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines

  Friday's session saw 75 companies set new 52-week lows.